Supernus director reports RSU-to-share conversion

Q: What insider transactions did SUPN director Charles W. Newhall III report?

He reported a routine RSU-to-share conversion. On February 24, 2026, 4,475 restricted stock units were disposed to the issuer and 4,475 shares of Supernus common stock were acquired at no cost as a grant or award acquisition.

Q: How many Supernus (SUPN) shares did the director acquire in this Form 4?

He acquired 4,475 common shares. The filing shows a grant or award acquisition of 4,475 shares at a price of $0.0000 per share, reflecting settlement of previously granted restricted stock units into common stock.

Q: What happened to the 4,475 restricted stock units reported for SUPN?

They were disposed to the issuer upon settlement. The Form 4 lists a disposition to the issuer of 4,475 restricted stock units at a price of $0.0000, corresponding to their conversion into an equal number of Supernus common shares for the reporting person.

Q: When will the reported SUPN restricted stock units vest and settle?

The units vest and settle on February 19, 2026. A footnote explains that each restricted stock unit converts into one share of Supernus common stock upon vesting, which is scheduled to occur on February 19, 2026, with settlement in common stock.

Q: What is Charles W. Newhall III’s Supernus (SUPN) shareholding after these transactions?

He directly holds 124,119 common shares. After the grant or award acquisition of 4,475 shares, the total number of Supernus common stock shares held directly by the reporting person increased to 124,119, as indicated in the Form 4.

Q: What do the Form 4 footnotes say about SUPN restricted stock units?

Each unit equals one common share at vesting. The footnotes state that every restricted stock unit represents the right to receive one share of Supernus common stock upon vesting, with settlement in common stock scheduled for February 19, 2026.

SUPERNUS PHARMACEUTICALS, INC. director Charles W. Newhall III reported routine equity transactions.

Accepted by SEC EDGAR 02/25/2026 - 04:57 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. director Charles W. Newhall III reported routine equity transactions. On February 24, 2026, 4,475 restricted stock units were disposed to the issuer and an equal 4,475 shares of common stock were acquired at no cost, bringing his direct holdings to 124,119 shares. Footnotes state each unit converts into one share, with vesting and settlement scheduled for February 19, 2026.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider NEWHALL CHARLES W III

Role Director

Type	Security	Shares	Price	Value
Disposition	Restricted Stock Unit	4,475	$0.00	$0.00
Grant/Award	Common Stock	4,475	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 124,119 shares (Direct)

Holdings Before and After: Restricted Stock Unit, 4,475 to 0 contracts (Direct); Common Stock, 119,644 to 124,119 shares (Direct)

Footnotes (2)

F1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F2. These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did SUPN director Charles W. Newhall III report?

He reported a routine RSU-to-share conversion. On February 24, 2026, 4,475 restricted stock units were disposed to the issuer and 4,475 shares of Supernus common stock were acquired at no cost as a grant or award acquisition.

How many Supernus (SUPN) shares did the director acquire in this Form 4?

He acquired 4,475 common shares. The filing shows a grant or award acquisition of 4,475 shares at a price of $0.0000 per share, reflecting settlement of previously granted restricted stock units into common stock.

What happened to the 4,475 restricted stock units reported for SUPN?

They were disposed to the issuer upon settlement. The Form 4 lists a disposition to the issuer of 4,475 restricted stock units at a price of $0.0000, corresponding to their conversion into an equal number of Supernus common shares for the reporting person.

When will the reported SUPN restricted stock units vest and settle?

The units vest and settle on February 19, 2026. A footnote explains that each restricted stock unit converts into one share of Supernus common stock upon vesting, which is scheduled to occur on February 19, 2026, with settlement in common stock.

What is Charles W. Newhall III’s Supernus (SUPN) shareholding after these transactions?

He directly holds 124,119 common shares. After the grant or award acquisition of 4,475 shares, the total number of Supernus common stock shares held directly by the reporting person increased to 124,119, as indicated in the Form 4.

What do the Form 4 footnotes say about SUPN restricted stock units?

Each unit equals one common share at vesting. The footnotes state that every restricted stock unit represents the right to receive one share of Supernus common stock upon vesting, with settlement in common stock scheduled for February 19, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NEWHALL CHARLES W III

(Last)

(First)

(Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE

20850

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/24/2026		A		4,475	A	$0	124,119	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	02/24/2026		D			4,475	⁽²⁾	⁽²⁾	Common Stock	4,475	$0	0	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

2. These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR